Effect of different 5-HT1A receptor antagonists in combination with paroxetine on expression of the immediate-early gene Arc in rat brain

Neuropharmacology

Volumn 44, Issue 7, 2003, Pages 893-902

  Tordera, R ^a   Pei, Q ^a   Newson, M ^a   Gray, K ^a   Sprakes, M ^a   Sharp, T ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

5 HT; 5 HT1A; Antidepressant; Arc; SSRI

Indexed keywords

1 CYCLOHEXYL 4 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 METHYL 2 PHENYL 1 BUTANONE; 4 (2' METHOXYPHENYL) 1 [2' [N (2'' PYRIDINYL) 4 IODOBENZAMIDO]PIPERAZINE]; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; LY 426965; MESSENGER RNA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; ROBALZOTAN; SEROTONIN 1A ANTAGONIST; SEROTONIN 2 AGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARC IMMEDIATE EARLY GENE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DRUG EFFECT; FRONTAL CORTEX; GENE EXPRESSION REGULATION; IMMEDIATE EARLY GENE; MALE; NONHUMAN; PARIETAL LOBE; PRIORITY JOURNAL; PUTAMEN; PYRIFORM CORTEX; RAT;

AMINOPYRIDINES; ANIMALS; APOPTOSIS REGULATORY PROTEINS; BENZOPYRANS; BRAIN CHEMISTRY; GENE EXPRESSION; MALE; MUSCLE PROTEINS; PAROXETINE; PIPERAZINES; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RNA, MESSENGER; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0037410250     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00096-0     Document Type: Article

References (37)

1. 1A receptor antagonist p-MPPI blocks responses mediated by postsynaptic and presynaptic 5-HT1A receptors. Pharmacology Biochemistry and Behaviour. 57:1997;301-307.
2. 1A receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. European Journal of Pharmacology. 382:1999;133-138.
3. Artigas F., Celada P., Laruelle M., Adell A. How does pindolol improve antidepressant action? Trends in Pharmacological Science. 22:2001;224-228.
4. Asberg M., Eriksson B., Martensson B., Traskman-Bendz L., Wagner A. Therapeutic effects of serotonin uptake inhibitors in depression. Journal of Clinical Psychiatry. 47:1986;23-35.
5. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends in Pharmacological Science. 15:1994;220-226.
6. 1A receptor antagonist, WAY 100,635, in the rat. Neuropharmacology. 39:2000;1222-1236.
7. 1A receptor antagonist co-administration. Journal of Neurochemistry (in press).
8. 1A receptors does not modify the effect of fluoxetine or 5-hydroxytryptophan on ethanol and food intake in rats. Psychopharmacology. 134:1997;55-63.
9. 1A receptor antagonist. Behavioural Brain Research. 73:1996;337-353.
10. Fosnaugh J.S., Bhat R.V., Yamagata K., Worley P.F., Baraban J.M. Activation of Arc, a putative 'effector' immediate early gene, by cocaine in rat brain. Journal of Neurochemistry. 64:1995;2377-2380.
11. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. British Journal of Pharmacology. 115:1995;1064-1070.
12. Gobert A., Dekeyne A., Millan M.J. The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572. Neuropharmacology. 39:2000;1608-1616.
13. 1B receptors with WAY 100,635 and GR 127,935. Journal of Neurochemistry. 68:1997;1159-1163.
14. 2C receptors. British Journal of Pharmacology. 124:1998;1781-1787.
15. 1A receptors. Neuroscience Letters. 304:2001;129-132.
16. Hajós-Korcsok E., McTavish S.F., Sharp T. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. European Journal of Pharmacology. 407:2000;101-107.
17. 1A receptor ligands on Fos-like immunoreactivity in rat brain: evidence for activation of noradrenergic transmission. Synapse. 34:1999;145-153.
18. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. Journal of Neurochemistry. 60:1993;776-779.
19. Hjorth S., Bengtsson H.J., Kullberg A., Carlzon D., Peilot H., Auerbach S.B. Serotonin autoreceptor function and antidepressant drug action. Journal of Psychopharmacology. 14:2000;177-185.
20. 1A receptor antagonist, NAD-299. Journal of Pharmacology and Experimental Therapeutics. 283:1997;216-225.
21. Kung H.F., Kung M.P., Clarke W., Maayani S., Zhuang Z.P. A potential 5-HT1A receptor antagonist: p-MPPI. Life Sciences. 55:1994;1459-1462.
22. 1A autoreceptors on serotonin release in prefrontal cortex and dorsal hippocampus of the same rat treated with fluoxetine. Chinese Journal of Physiology. 42:1999;53-59.
23. Lyford G.L., Yamagata K., Kaufmann W.E., Barnes C.A., Sanders L.K., Copeland N.G., Gilbert D.J., Jenkins N.A., Lanahan A.A., Worley P.F. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron. 14:1995;433-445.
24. 1A receptor antagonists on dorsal raphe cell firing. Journal of Pharmacology and Experimental Therapeutics. 288:1999;820-826.
25. 1B receptors. European Journal of Pharmacology. 321:1997;R11-R13.
26. 1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats. European Journal of Pharmacology. 372:1999;127-134.
27. Nemeroff C.B. The neurobiology of depression. Scientific American. 278:1998;42-49.
28. 1A receptor mutant mice exhibit enhanced tonic, stress-induced and fluoxetine-induced serotonergic neurotransmission. Journal of Neurochemistry. 77:2001;607-617.
29. Paxinos G., Watson C. The rat brain in stereotaxic co-ordinates. 1986;Academic Press, Sydney.
30. Pei Q., Lewis L., Sprakes M.E., Jones E.J., Grahame-Smith D.G., Zetterstrom T.S. Serotonergic regulation of mRNA expression of Arc, an immediate early gene selectively localized at neuronal dendrites. Neuropharmacology. 39:2000;463-470.
31. 1A receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology. 23:2000;285-293.
32. 1A antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. Journal of Pharmacology and Experimental Therapeutics. 294:2000;688-700.
33. 1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. Journal of Neurochemistry. 68:1997;2593-2603.
34. 1-adrenoceptors in the inhibition of 5-HT release-II NAN-190 and SDZ 216-525. Neuropharmacology. 35:1996;735-741.
35. Thielen R.J., Fangon N.B., Frazer A. 4-(2'-Methoxyphenyl)-1-[2'-[N-(2'-pyridinyl)-p-iodobenzamido]ethyl] piperazine and 4-(2'-methoxyphenyl)-1-[2'-[N-(2'-pyridinyl)-p- fluorobenzamido]ethyl]piperazine, two new antagonists at pre- and postsynaptic serotonin-1A receptors. Journal of Pharmacology and Experimental Therapeutics. 277:1996;661-670.
36. 1A antagonists, NAD-299 and LY 426965, on expression of the immediate early gene Arc in the rat brain. British Journal of Pharmacology. 135:2002;P379.
37. 1A receptor antagonists. European Journal of Pharmacology. 357:1998;179-184.